Learn everything you need to know about Repaglinide and Metformin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, ...

Repaglinide belongs to a group of diabetes drugs called meglitinides. It comes as a tablet you take by mouth. Keep reading for details on repaglinide and cost, and how to save money on prescriptions.

Review the side-effects of Repaglinide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

May 16, 2003 — In two separate randomized trials presented at the American Academy of Clinical Endocrinology annual meeting, repaglinide was more effective than nateglinide in type 2 diabetes.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Lean older adults with type 2 diabetes experienced lower ...

Type 2 diabetes care often targets both fasting and post-meal glucose. Repaglinide is a short-acting option for postprandial control. Its safety profile is tightly linked to meal timing, ...

Washington, DC - The FDA and Novo Nordisk have revised the drug interaction section of the insulin secretagogue repaglinide (Prandin ®) to indicate a possible adverse reaction with the lipid-lowering ...

Several markers of inflammation and endothelial dysfunction are associated with the elevated risk of cardiovascular disease (CVD) seen in patients with type 2 diabetes, independently of conventional ...

The benefit of glinides in the treatment of type 2 diabetes is not scientifically proven. Nor do they perform better than other oral antidiabetics (metformin, sulfonylureas). Although glinides have ...

DETROIT, Aug. 13Â -- Caraco Pharmaceutical Laboratories, Ltd., announced today that the US Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug ...

BAGSVAERD, DENMARK--(Marketwired - Jun 18, 2013) - Today, the U.S. Court of Appeals for the Federal Circuit partially affirmed a 2011 District Court decision, with a 2-1 ruling that a claim in a Novo ...